Patents by Inventor Fengtian Xue

Fengtian Xue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GALLIUM-SALOPHEN ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20230227476
    Abstract: Gallium-salophen compounds, and methods of using the same for the treatment of disease are disclosed.
    Type: Application
    Filed: June 4, 2021
    Publication date: July 20, 2023
    Inventors: Fengtian XUE, Angela WILKS
  • Car activator agents for cyclophosphamide-based treatments of cancer
    Patent number: 11701345
    Abstract: The invention relates to selective small molecule human constitutive androstane receptor (hCAR) activators of Formula (I) or (II), pharmaceutical compositions thereof, and use thereof for the treatment of hematologic malignancies and other cancers. The small molecule hCAR activator in combination with CPA based chemotherapy regimen provides a synergistic effect to help promote cytoxicity of the cyclophosphamide (CPA) based anticancer treatments including CHOP regimen (CPA, doxorubicin, vincristine, and prednisone) by preferential induction of CYP2B6 over CYP3A4 and promoting the formation of therapeutically active CPA metabolite 4-OH-CPA.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: July 18, 2023
    Assignee: University of Maryland, Baltimore
    Inventors: Hongbing Wang, Fengtian Xue, Dongdong Liang
  • WNT signaling pathway inhibitors for treatments of disease
    Patent number: 11655233
    Abstract: Compounds and compositions are provided as inhibitors of the Wnt/?-catenin pathway for the treatment of diseases that implicate the same.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: May 23, 2023
    Assignee: University of Maryland, Baltimore
    Inventors: Fengtian Xue, Yan Shu
  • CAR AND NRF2 DUAL ACTIVATOR AGENTS FOR CYCLOPHOSPHAMIDE-BASED AND DOXORUBICIN-BASED TREATMENTS OF CANCER
    Publication number: 20230134760
    Abstract: The disclosure relates to selective small molecule dual activators of human constitutive androstane receptor (hCAR) and nuclear factor erythroid 2-related factor 2 (Nrf2), pharmaceutical compositions thereof, and use thereof for the treatment of hematologic malignancies and other cancers. The small molecule dual hCAR and Nrf2 activators in combination with CPA based chemotherapy regimen provides a synergistic effect to help promote cytoxicity of the cyclophosphamide (CPA) based and doxorubicin (DOX) based anticancer treatments including CHOP regimen (CPA, doxorubicin, vincristine, and prednisone) while reducing cardiotoxicity associated with DOX.
    Type: Application
    Filed: March 4, 2021
    Publication date: May 4, 2023
    Inventors: Hongbing Wang, Fengtian Xue, Linhao LI
  • PRODRUGS OF ANTI-CANCER AND ANTI-AUTOIMMUNE DISEASES THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USE THEREOF
    Publication number: 20220041627
    Abstract: The invention relates to prodrugs of anti-cancer and anti-autoimmune diseases therapeutic agents, and methods of making and use thereof.
    Type: Application
    Filed: December 4, 2019
    Publication date: February 10, 2022
    Inventors: Fengtian XUE, Yan SHU, Yong AI
  • Wnt signaling pathway inhibitors for treatments of disease
    Patent number: 10882841
    Abstract: Compounds and compositions are provided as inhibitors of the Wnt/?-catenin pathway for the treatment of diseases that implicate the same.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: January 5, 2021
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Fengtian Xue, Yan Shu
  • CAR ACTIVATOR AGENTS FOR CYCLOPHOSPHAMIDE-BASED TREATMENTS OF CANCER
    Publication number: 20200352915
    Abstract: The invention relates to selective small molecule human constitutive androstane receptor (hCAR) activators of Formula (I) or (II), pharmaceutical compositions thereof, and use thereof for the treatment of hematologic malignancies and other cancers. The small molecule hCAR activator in combination with CPA based chemotherapy regimen provides a synergistic effect to help promote cytoxicity of the cyclophosphamide (CPA) based anticancer treatments including CHOP regimen (CPA, doxorubicin, vincristine, and prednisone) by preferential induction of CYP2B6 over CYP3A4 and promoting the formation of therapeutically active CPA metabolite 4-OH-CPA.
    Type: Application
    Filed: June 19, 2018
    Publication date: November 12, 2020
    Inventors: Hongbing WANG, Fengtian XUE, Dongdong LIANG
  • WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE
    Publication number: 20200299261
    Abstract: Compounds and compositions are provided as inhibitors of the Wnt/?-catenin pathway for the treatment of diseases that implicate the same.
    Type: Application
    Filed: June 12, 2020
    Publication date: September 24, 2020
    Inventors: Fengtian XUE, Yan SHU
  • Wnt signaling pathway inhibitors for treatments of disease
    Patent number: 10723715
    Abstract: Compounds and compositions are provided as inhibitors of the Wnt/?-catenin pathway for the treatment of diseases that implicate the same.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: July 28, 2020
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Fengtian Xue, Yan Shu
  • Compounds for treating parasitic infections
    Patent number: 10662168
    Abstract: Compounds and compositions comprising them are provided. The compounds and compositions are useful for inhibiting transport of heme across membranes in parasitic heme auxotrophic organisms, thereby limiting their growth or killing the parasites.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: May 26, 2020
    Assignees: University of Maryland, College Park, University of Maryland, Baltimore
    Inventors: Iqbal Hamza, Fengtian Xue
  • COMPOUNDS FOR TREATING PARASITIC INFECTIONS
    Publication number: 20190152938
    Abstract: Compounds and compositions comprising them are provided. The compounds and compositions are useful for inhibiting transport of heme across membranes in parasitic heme auxotrophic organisms, thereby limiting their growth or killing the parasites.
    Type: Application
    Filed: January 29, 2019
    Publication date: May 23, 2019
    Inventors: Iqbal HAMZA, Fengtian XUE
  • Compounds for treating parasitic infections
    Patent number: 10227320
    Abstract: Compounds and compositions comprising them are provided. The compounds and compositions are useful for inhibiting transport of heme across membranes in parasitic heme auxotrophic organisms, thereby limiting their growth or killing the parasites.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: March 12, 2019
    Assignees: University of Maryland, College Park, University of Maryland, Baltimore
    Inventors: Iqbal Hamza, Fengtian Xue
  • WNT Signaling Pathway Inhibitors for Treatments of Disease
    Publication number: 20190071424
    Abstract: Compounds and compositions are provided as inhibitors of the Wnt/?-catenin pathway for the treatment of diseases that implicate the same.
    Type: Application
    Filed: March 1, 2017
    Publication date: March 7, 2019
    Inventors: Fengtian XUE, Yan SHU
  • BCL6 inhibitors as anticancer agents
    Patent number: 9943506
    Abstract: The invention provides compositions and methods for blocking the BCL6 BTB domain with small molecule, non-peptide compounds as disclosed and claimed herein. BCL6 is a transcriptional repressor of the BTB-POZ (brie a brae, tramtrack, broad complex/pox virus zincfinger) family of proteins. It is required for normal development of germinal center (GC) B-cells and is also the most commonly involvedoncogene in diffuse large B-celllymphomas (DLBCLs), and constitutive expression of BCL6 in GC B-cells causes DLBCL in mice.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: April 17, 2018
    Assignees: Cornell University, University of Maryland, Baltimore
    Inventors: Ari Melnick, Leandro Carlos A. Cerchietti, Mariano G. Cardenas, Fengtian Xue, Alexander D. MacKerell
  • Intramolecular hydrogen-bonded nitric oxide synthase inhibitors
    Patent number: 9765055
    Abstract: Compounds and related compositions and methods as can be used to selectively inhibit neuronal nitric oxide synthase and as can be employed in the treatment of various neurodegenerative diseases.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: September 19, 2017
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Fengtian Xue
  • Chiral synthesis of pyrrolidine core compounds en route to neuronal nitric oxide synthase inhibitors
    Patent number: 9758507
    Abstract: A chiral synthesis of pyrrolidine compounds en route to selective neuronal nitric oxide synthase inhibitors, and representative inhibitor compounds heretofore unattainable.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: September 12, 2017
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Fengtian Xue
  • LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders
    Patent number: 9701627
    Abstract: Compounds, and methods of using the same, are provided as therapies for the treatment leucine-rich repeat kinase-2 (LRRK2)-related disorders including, but not limited to, neurodegenerative and neuroinflammatory disorders, such as Parkinson's Disease.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: July 11, 2017
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Wanli Smith, Fengtian Xue, Alexander D MacKerell, Jr.
  • BCL6 INHIBITORS AS ANTICANCER AGENTS
    Publication number: 20160166549
    Abstract: The invention provides compositions and methods for blocking the BCL6 BTB domain with small molecule, non-peptide compounds as disclosed and claimed herein. BCL6 is a transcriptional repressor of the BTB-POZ (brie a brae, tramtrack, broad complex/pox virus zincfinger) family of proteins. It is required for normal development of germinal center (GC) B-cells and is also the most commonly involvedoncogene in diffuse large B-celllymphomas (DLBCLs), and constitutive expression of BCL6 in GC B-cells causes DLBCL in mice.
    Type: Application
    Filed: June 16, 2014
    Publication date: June 16, 2016
    Inventors: Ari Melnick, Leandro Carlos A. Cerchietti, Mariano G. Cardenas, Fengtian Xue, Alexander D. MacKerell
  • Chiral Synthesis of Pyrrolidine Core Compounds en route to Neuronal Nitric Oxide Synthase Inhibitors
    Publication number: 20160096821
    Abstract: A chiral synthesis of pyrrolidine compounds en route to selective neuronal nitric oxide synthase inhibitors, and representative inhibitor compounds heretofore unattainable.
    Type: Application
    Filed: December 14, 2015
    Publication date: April 7, 2016
    Inventors: Richard B. Silverman, Fengtian Xue
  • LRRK2 GTP BINDING INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE AND NEUROINFLAMMATORY DISORDERS
    Publication number: 20150361038
    Abstract: Compounds, and methods of using the same, are provided as therapies for the treatment leucine-rich repeat kinase-2 (LRRK2)-related disorders including, but not limited to, neurodegenerative and neuroinflammatory disorders, such as Parkinson's Disease.
    Type: Application
    Filed: June 16, 2015
    Publication date: December 17, 2015
    Inventors: Wanli Smith, Fengtian Xue, Alexander D. MacKerell, JR.